Results²

Clinical Implications²

Study Design¹

2,659 individuals were randomized to either immediate monitoring with an iRhythm Zio patch, or delayed monitoring to be initiated 4 months after consent.

Participants were asked to wear the patch for 2 weeks, on 2 different occasions, at the beginning and the end of a 4 month active monitoring period.

Participants were:

• Identified through claims analysis
• Randomized to receive immediate or delayed monitoring
• Received routine care during unmonitored periods

In addition, for each monitored participant, up to 2 observational control participants (matched for age, sex, and CHA₂DS₂VASc score) were identified from the pool of eligible members who did not receive an invitation.

The primary endpoint was the incidence of newly diagnosed AF, either clinically or through monitoring in the immediate cohort (defined by ≥30 seconds of atrial fibrillation or flutter), compared with clinical monitoring alone in the delayed cohort.